A data-driven wellness solution with fatigue monitoring capabilities using scheduling insights enables law enforcement agencies to take a proactive approach to officer health and well-being.
…
DoD and VA Healthcare Facilities Can Now Purchase UroViu’s Single-Use Endoscopy Products
LOS ALTOS, Calif. – October 13, 2022 – (Newswire.com)
UroViu Corp, a company that develops and commercializes highly portable single-use endoscopy platforms, announced today that it has been added to the US Defense Logistics Agency’s Medical Equipment ECAT. With a contract secured through Fidelis Sustainability Distribution, Veterans will now have access to the latest endoscopy products on the market.
Under the agreement, UroViu will sell its entire product line at a contracted price for distribution exclusively through Fidelis to over 1,200 VA and DOD healthcare facilities throughout the United States that serve 9 million enrolled Veterans each year.
“Urology is the second most common indication by procedure volume in the Veterans Health Administration (VHA) representing a large market for UroViu,” said Sebastien Cadet, Chief Commercial Officer of UroViu Corp. “ECAT is the most convenient and cost-effective way to deliver our products to all government facilities. It is with great pride we can now efficiently support our Veterans.”
Single-use endoscopy is a safer and more reliable alternative to traditional reusable scopes which must be cleaned, disinfected, and sanitized after every use. The difficulty of servicing traditional scopes has led to FDA scrutiny due to cross-contamination risks. UroViu’s single-use scopes eliminate those risks. The single-use platform ranges from a 12-Fr diagnostic semi-rigid cystoscope and equivalent hysteroscope, a 14-Fr injection cystoscope with an integrated needle for drug delivery, to a flexible, deflectable, and rotatable 16.5-Fr cystoscope have the potential to help any government facilities improve care and efficiency.
“Fidelis’ SDVDSB status provides UroViu with preferential access to secure VHA and DOD contracts,” said Joel Kohn, President of Fidelis Sustainability Distribution, LLC. “More importantly, we help streamline the procurement process thus accelerating the delivery of cutting-edge technologies such as UroViu’s single-use endoscopes that our Veterans deserve.”
About UroViu Corporation
UroViu Corporation’s mission is to revolutionize the endoscopy platform for improved patient care and provider efficiency with operations in California and Washington and production facilities in Asia. UroViu is the developer of the always-ready cystoscopy & hysteroscopy platforms, the highly portable, self-contained, and versatile single-use endoscopy solution to meet the needs of Urologists, UroGynecologists, and Gynecologists. The unique portable platform and product suite are protected by a portfolio of 20+ patents granted worldwide and many more pending patents. UroViu’s vision is to simplify the scope of patient care. For more information please visit www.uroviu.com.
About Fidelis Sustainability Distribution
Fidelis Sustainability Distribution, LLC, (FSD) is a Nevada-based, Service-Disabled Veteran-Owned Small Business (SDVOSB) focused on helping streamline the acquisition of medical/dental technology in US Government facilities. Our firsthand industry experience of how technology moves from concept to commercialization and through healthcare supply chains enables us to support our manufacturing partners and Government customers alike at the highest level. Since 2014, FSD has secured over $80M+ in positive past performance and is dedicated to serving all major Federal Healthcare facilities including 170+ VAMC’s, 1,000+ CBOC’s,150+ DOD Medical Facilities, and Health and Human Services (HHS).
Contact Information:
Lisa Sorbo
Marketing Manager, UroViu Corp
[email protected]
941-667-0043
Press Release Service
by
Newswire.com
Original Source:
UroViu Corp Secures Medical Equipment ECAT Contract for VA DoD Purchasing
Dr. Andrea Small-Howard discusses the company’s novel process for developing disease-specific, cannabinoid-based therapeutics.
LAS VEGAS – October 13, 2022 – (Newswire.com)
Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, is demonstrating the potential efficacy of their proprietary cannabis-inspired mixtures today at the Canna Pharma 2022 Conference in San Diego, California. Dr. Small-Howard explains Gb Sciences’ novel process for developing disease-specific, cannabinoid therapeutics in her presentation entitled “Case Studies: Identification of Minimum Essential Therapeutic Mixtures from Cannabis Plant Extracts by Screening in Cell and Animal Models.” Gb Sciences’ case studies include scientific evidence demonstrating the potential efficacy of their cannabinoid-based therapeutic mixtures designed to treat Parkinson’s disease, chronic pain, or inflammation using their novel minimal essential mixture approach.
“Medicinal cannabis has shown great promise for the symptomatic treatment of many serious human disorders, but concerns around safety, consistency, legality, psychoactivity, and non-standardized routes of delivery, such as smoking and vaping, have slowed the adoption of the use of medical cannabis within traditional, physician-guided patient treatment programs. To address these challenges, we hypothesized that within Cannabis plant extracts, there would be a minimal essential mixture of compounds that preserves whole plant benefits, but with the manufacturing, quality control, and regulatory benefits of single ingredient therapies,” said Dr. Andrea Small-Howard.
Minimal essential mixtures (MEM) is a term Gb Sciences has coined from their proprietary research after deeming that a simplified mixture represented a happy medium between whole plant medicines and single ingredient drugs. Minimum Essential Mixtures are designed to retain increased therapeutic effectiveness from molecular synergies within the original plant extracts, but with the manufacturing efficiencies, quality assurances, and regulatory advantages of single ingredient drugs. Gb Sciences’ disease-specific MEM are produced for clinical evaluation using synthetic homologs of cannabis-based ingredients incorporated into sophisticated oral delivery modalities including Oral Dissolving Tablets (ODT), Oral Thin Films (OTF), time-released oral nanoparticles, and gel capsules to increase the stability, bioavailability, and ease-of-use of these ingredients relative to the non-standardized delivery methods used for Cannabis plant extracts.
Gb Sciences was recently published in Pharma’s Almanac discussing the strategy behind their plant-inspired minimum essential mixtures, which provides context for the case studies being presented today.
To learn more about Gb Sciences, visit www.gbsciences.com.
About Gb Sciences and GbS Global Biopharma
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Contact Information:
Madeleine Moench
[email protected]
Press Release Service
by
Newswire.com
A recent study published in the journal Environment International found plastic particles in blood samples in 80% of people tested. The effects of microplastics in the body aren’t known – but researchers said the new results areconcerning and that microplastics could damage human cells. Neil and Roy look at the vocabulary used in the headlines […]
Will Be the Only Provider in King County Awarded the Competitive Grant
TUKWILA, Wash. – October 12, 2022…
Affiliation marks continued growth for Great Expressions in the Northeast
SOUTHFIELD, Mich. – October 12…
Signs New Distribution Partners in Three Countries
LAWRENCEVILLE, Ga. – October 12, 2022 …
Expansion exemplifies the company’s commitment to meet the highest security and compliance standards
TORONTO – October 12, 2022 – (Newswire.com)
Smile CDR Inc. (doing business as Smile Digital Health), a leading health data and integration company, today announced it has passed an Amazon Web Services (AWS) Foundational Technical Review (FTR) and has achieved Amazon HealthLake (AHL) Connector partner status in the AWS Partner Network (APN). Healthcare organizations can expect Smile Digital Health running on AWS to provide a best-in-class data fabric platform along with the confidence that it is meeting various regulatory and compliance requirements in the U.S. and the EU when storing and sharing their sensitive health data via the platform. Smile Digital Health first announced its work with AWS in March, and this expansion represents the continual growth of that relationship.
“Our ongoing work with AWS demonstrates the deep collaboration between our companies, delivering the many benefits of the Smile Digital Health data fabric platform running in a world-class hyperscale environment. Having partner status provides our customers with substantial benefits including additional security, dependability and operational excellence,” said Duncan Weatherston, Chief Executive Officer, Smile Digital Health. “Healthcare organizations — and in turn their patients — are well served by access to our scalable, high-performing, resilient and efficient data fabric platform on the leading cloud infrastructure.”
The expansion and scope of work includes two key elements:
“Our customers can expect Smile Digital Health to continuously meet and often exceed regulatory and compliance requirements when storing and sharing their sensitive health data via our data fabric platform. In that sense, we continue to guarantee the highest security and compliance standards,” said James Agnew, Chief Technology Officer, Smile Digital Health.
Smile Digital Health’s work on AWS continues to simplify the interoperability process between various data platforms, allowing for better health journey outcomes between patients, providers and health systems, and reducing information technology barriers.
About Smile Digital Health
Smile Digital Health is a health information technology company focused on delivering better global health through open standards. Our enterprise-grade, health data fabric and exchange platform fuels healthcare’s digital transformation and accelerates value creation across all patient journeys at scale. | Part of VUGA Media Group | Fair Use | Terms of Use | Get Published our HL7® FHIR® standard-based clinical data repository (#SmileInside), our platform enables collaboration and allows organizations to ingest, transform, store, enrich, analyze, aggregate, and meaningfully share health information to power digital transformation. We prepare healthcare providers, payers, researchers, and life sciences organizations for a connected future beyond legacy systems, adding new value through intelligent use of information and ultimately delivering better patient outcomes. We help healthcare organizations confidently #ChooseOpenStandards with the goal of #BetterGlobalHealth. For more information, visit SmileDigitalHealth.com.
Contact Information:
Lucy Railton
Director of Marketing
[email protected]
(800) 683-1318
Press Release Service
by
Newswire.com
Original Source:
Smile Digital Health Expands Work on AWS
Signs New Distribution Partners in Three Countries
LAWRENCEVILLE, Ga. – October 12, 2022 …
Designee builds on commitment to furthering excellence in the healthcare sector’s information security and privacy programs
PORTLAND, Ore. – October 12, 2022 – (Newswire.com)
Apgar & Associates, LLC today announced that it is designated as a HITRUST Readiness Licensee. With this achievement, Apgar & Associates is approved by HITRUST to perform consulting and readiness work for organizations looking to adopt the HITRUST CSF or prepare for their first assessment. For over a decade, the consultancy has provided information security and privacy services that encompass strategic planning for risk management and compliance programs, as well as consulting on security incidence response, risk analysis, and policy and procedures.
HITRUST Readiness Licensees help uphold information security and privacy standards for various industries of varying size and complexity by assisting clients with the adoption of the HITRUST CSF framework, implementation, and remediation efforts following adoption, and facilitated self-assessments.
“We’re very pleased to receive the HITRUST Readiness designation. It feels like a natural progression in our firm’s commitment to furthering excellence in the healthcare sector’s information security and privacy programs,” stated Julia Huddleston, CIPP/US, CIPM, CCSFP, and Principal Consultant at Apgar & Associates, LLC. “We look forward to helping guide healthcare providers and their business associates through the what and how of readying for the HITRUST assessment.”
“Readiness Licensees meet the criteria to become trusted and independent resources for clients needing to improve their security posture,” said Matthew Datel, Director, Education & Strategic Initiatives at HITRUST. “Readiness Licensees are helpful in providing qualified third-party reviews for clients preparing for or seeking HITRUST CSF Certification.”
About Apgar & Associates
The consultancy’s information security and privacy services encompass strategic planning for risk management and compliance programs, as well as consulting on security incidence response, risk analysis, and policy and procedures.
The team also helps organizations decide which of the various industry certifications aligns best with the business’ privacy and information security strategy. For more information about Apgar & Associates’ consulting services, such as HITRUST Readiness, please contact the company at 503-384-2538 or visit its website at https://apgarandassoc.com/.
Contact Information:
Nora Haile
Marketing Consultant
[email protected]
520-425-6498
Press Release Service
by
Newswire.com
Original Source:
Apgar & Associates Achieves HITRUST® Readiness Licensee Designation
Copyright © 2025 | WordPress Theme by MH Themes